Ketamine as an Adjunctive Therapy for Major Depression (2)
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
Pragmatic, randomised, controlled, parallel-group, superiority trial of ketamine vs.
midazolam as an adjunctive therapy for depression. The main purpose of the trial is to assess
the mood-rating score difference between ketamine and midazolam from before the first
infusion to 24 hours after the final infusion, supplemented by a 95% confidence interval.
There will also be a 24-week follow-up after the final infusion session.